Tavalisse (Fostamatinib Disodium) Patent Expiration, LOE Window & CMS Spending

Tavalisse (Fostamatinib Disodium) by Rigel Pharmaceuticals: FDA Orange Book core substance LOE 2031-09-04 (last listed 2032-07-27), 1 AB generics, $62.3M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRigel Pharmaceuticals
FDA Application & PathwayN209299 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-09-04
Last Listed Patent or Exclusivity Date2032-07-27
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$62.3M
2024 Medicare Part D Spend$47.4M
2024 Medicaid Spend$14.9M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 17.9% 2-yr change)